Jefferies Reiterates Underperform Rating, $4 PT on Halozyme Therapeutics
In a report published Wednesday, Jefferies reiterated its Underperform rating and $4.00 price target on Halozyme Therapeutics (NASDAQ: HALO).
Jefferies noted, “SC Herceptin EU approval is expected in 1H13; its commercial success will be key to ultimate validation of rHuPH20 technology & further valuation upside in HALO. We continue to view SC Herceptin commercial potential as low. Given delays in Herceptin biosimilar EU market entry & potentially expedited development of its T-DM1 in HER2+ BC adjuvant setting, Roche's focus on SC Herceptin seems to have diminished.”
Halozyme Therapeutics closed on Tuesday at $8.03.
Latest Ratings for HALO
Date | Firm | Action | From | To |
---|---|---|---|---|
Dec 2020 | Berenberg | Initiates Coverage On | Buy | |
Nov 2020 | Wells Fargo | Maintains | Overweight | |
Jul 2020 | Piper Sandler | Maintains | Overweight |
View More Analyst Ratings for HALO
View the Latest Analyst Ratings
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: JefferiesAnalyst Color Reiteration Analyst Ratings